Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stockUpcoming Result Date: May 21, 2026
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Sun Pharmaceutical Industries Ltd (SUNPHARMA) is currently trading at 1,886.45 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Sun Pharmaceutical Industries Limited is a global specialty generic and innovative medicines company that researches, manufactures and markets branded generics, generics, complex formulations, APIs and innovative specialty products across over 100 countries, with a 40-site global manufacturing footprint and roughly 43,000 employees focused on dermatology, ophthalmology, oncology and chronic therapies. The company reported FY25 consolidated sales of Rs 520 billion and has delivered a 19% sales CAGR since FY10, with Innovative Medicines growing to 20% of revenues; Sun Pharma combines a diversified geographic split—India 33% and international 67%—with deep backward integration into APIs and multiple dosage-form capabilities. Sun Pharma exhibits best-in-class profitability among Indian peers: FY25 gross margin ~79.3%, EBITDA margin ~29.0% and ROCE ~20.4%, supported by strong operating cash flow and a net cash position of Rs 267.9 billion, enabling continued R&D investment and selective M&A while maintaining balance sheet strength. Innovative Medicines are an accelerating growth engine for Sun Pharma: FY25 Innovative sales were USD 1,216 million with Ilumya accounting for USD 681 million, a pipeline of five new active substances plus late-stage candidates, and cumulative R&D investment of ~Rs 325 billion, signalling a strategic shift toward higher-margin specialty products. Strategic priorities include mid to high single-digit consolidated revenue guidance for FY26, continued focus on expanding Innovative and complex offerings in the US and RoW, disciplined M&A and partnerships to fill pipeline gaps, and embedding sustainability targets including renewable energy and emissions and water reduction commitments.
Over the past 52 weeks, Sun Pharmaceutical Industries Ltd has traded between a low of ₹1,547.25 and a high of ₹1,917.15. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Sun Pharmaceutical Industries Ltd has a market capitalization of approximately 4,51,194.94. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Sun Pharmaceutical Industries Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 41.34 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 4,51,194.94 Cr, Sun Pharmaceutical Industries Ltd is classified as a Large Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Sun Pharmaceutical Industries Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Sun Pharmaceutical Industries Ltd is 41.34. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Sun Pharma will pay US$ 14.00 per Organon share in an all-cash deal valuing Organon at an enterprise value of about US$ 11.75 billion.
Sun Pharma will pay US$14.00 per Organon share in an all-cash transaction, valuing Organon at an enterprise value of US$11.75 billion.
Sun Pharma will acquire Organon for US$ 14.00 per share in an all-cash transaction with an enterprise valuation of US$ 11.75 billion.
Sun Pharma shares rose 7.03% on Monday after it signed an agreement to acquire Organon in an all-cash transaction, prompting multiple brokerages to turn more constructive.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
1882.15 | 4,51,195 Cr | 41.34 | 5.80 | 0.85 | 14.84 | 18.86 | 10.61 | ||
6755.00 | 1,82,993 Cr | 73.82 | 11.87 | 0.43 | 16.12 | 20.29 | 13.66 | ||
4457.15 | 1,49,926 Cr | 65.99 | 17.74 | 0.14 | 25.33 | 27.37 | 14.64 | ||
1361.00 | 1,13,052 Cr | 29.14 | 3.28 | 0.93 | 11.27 | 14.95 | 9.11 | ||
1307.00 | 1,10,333 Cr | 26.29 | 2.91 | 0.61 | 11.07 | 12.54 | 7.15 | ||
2507.00 | 1,06,669 Cr | 55.76 | 6.54 | 0.00 | 11.74 | 13.13 | 6.90 | ||
864.25 | 1,04,744 Cr | 20.78 | 3.86 | 0.10 | 18.59 | 17.35 | 9.59 | ||
| Median: 7 Co. | — | 1882.15 | 1,13,052 Cr | 41.34 | 5.80 | 0.43 | 14.84 | 17.35 | 9.59 |
Bearish
1
Neutral
8
Bullish
5
Bearish
3
Neutral
8
Bullish
35
Bearish
2
Neutral
0
Bullish
30
Sun Pharmaceutical Industries Limited is a global specialty generic and innovative medicines company that researches, manufactures and markets branded generics, generics, complex formulations, APIs and innovative specialty products across over 100 countries, with a 40-site global manufacturing footprint and roughly 43,000 employees focused on dermatology, ophthalmology, oncology and chronic therapies.
The company reported FY25 consolidated sales of Rs 520 billion and has delivered a 19% sales CAGR since FY10, with Innovative Medicines growing to 20% of revenues; Sun Pharma combines a diversified geographic split—India 33% and international 67%—with deep backward integration into APIs and multiple dosage-form capabilities.
Sun Pharma exhibits best-in-class profitability among Indian peers: FY25 gross margin ~79.3%, EBITDA margin ~29.0% and ROCE ~20.4%, supported by strong operating cash flow and a net cash position of Rs 267.9 billion, enabling continued R&D investment and selective M&A while maintaining balance sheet strength.
Innovative Medicines are an accelerating growth engine for Sun Pharma: FY25 Innovative sales were USD 1,216 million with Ilumya accounting for USD 681 million, a pipeline of five new active substances plus late-stage candidates, and cumulative R&D investment of ~Rs 325 billion, signalling a strategic shift toward higher-margin specialty products.
Strategic priorities include mid to high single-digit consolidated revenue guidance for FY26, continued focus on expanding Innovative and complex offerings in the US and RoW, disciplined M&A and partnerships to fill pipeline gaps, and embedding sustainability targets including renewable energy and emissions and water reduction commitments.
Pharmaceuticals & Biotechnology
Pharmaceuticals
4,52,623 Cr
Low Risk
41.5
34.8
1.9
5.8
1,917.15
1,547.25
Sales CAGR
Profit CAGR
ROE
ROCE
